Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
-
1
Dana-Farber research led to an FDA label update for CAR T-cell therapy, removing exclusions for primary CNS lymphoma patients.
-
2
The update expands access to axicabtagene ciloleucel (Yescarta) for eligible patients with relapsed or refractory CNS lymphoma.
-
3
Prior CAR T-cell trials excluded CNS lymphoma patients due to concerns about increased neurologic toxicity.
-
4
A pilot study at Dana-Farber demonstrated the safety and feasibility of CAR T-cell therapy in CNS lymphoma patients.
-
5
The FDA's decision allows eligible patients to receive CAR T-cell therapy after prior treatments, improving their options.
